• Fasudil (HA-1077) HCl: An Assay-First ROCK Guide

  2026-08-25

  Fasudil (HA-1077) HCl is a selective ROCK inhibitor for dissecting Rho/ROCK-dependent motility, proliferation, and apoptosis. This assay-first guide connects its target-engagement logic with the 2025 quercetin–Hippo cataract study while defining practical controls, readouts, and interpretation limits.

• Sulfo-NHS-Biotin for EV Protein Labeling

  2026-08-25

  Sulfo-NHS-Biotin converts accessible primary amines into stable biotin tags for tracking extracellular vesicles, validating cell-surface exposure, and enriching protein complexes. This guide connects a practical amine-labeling workflow with the emerging EV-based targeted protein degradation platform, while separating analytical labeling from therapeutic mechanism.

• Fluorescein TSA Fluorescence System Kit for IHC

  2026-08-24

  Improve visualization of scarce proteins, transcripts, and signaling markers in fixed cells and tissues with localized tyramide deposition. This practical guide connects the kit to the hypothalamic SLC7A14–POMC research model and provides starting conditions for IHC, ICC, and ISH optimization.

• DAMGO in µ-Opioid Receptor Signaling

  2026-08-23

  DAMGO is a selective µ-opioid receptor agonist for separating receptor-proximal signaling from the broader effects of morphine. This practical guide connects cell-based assays, tissue pharmacology, and brain-circuit pain models to improve opioid receptor signaling research and chronic pain research.

• Cefazedone PK/PD in Community-Acquired Pneumonia

  2026-08-22

  This clinical pharmacokinetic and pharmacodynamic study evaluated whether intravenous cefazedone sodium at 2 g every 12 hours provides rational exposure for mild to moderate community-acquired pneumonia. Despite its small, noncontrolled design, the study connected cefazedone exposure, isolate susceptibility, time above MIC, and clinical response, offering a practical framework for exposure-guided interpretation of this time-dependent antibiotic.

• PPT Workflows for ERα Signaling and LUAD

  2026-08-21

  PPT enables controlled ERα activation while reducing ERβ-driven ambiguity in gene-expression, oncology, and receptor-subtype experiments. This practical guide connects selective pharmacology with the FOXM1–miR-204-5p–ERα axis reported in female lung adenocarcinoma research.

• ECL Western Blotting Substrate: Practical Guide

  2026-08-21

  ECL Western Blotting Substrate (SKU K2187) is a luminol-based, nonradioactive horseradish peroxidase detection reagent for sensitive protein detection by chemiluminescence in Western blot assays. It is intended for HRP-based immunoblots using X-ray film or CCD imaging, not for fluorescent or radioisotopic detection workflows.

• Gepotidacin: From Target to Assay Design

  2026-08-20

  Gepotidacin (GSK2140944) demands more than a conventional MIC readout. This guide translates its topoisomerase mechanism into extracellular, intracellular, and PK/PD assay decisions for antibacterial research and antibiotic resistance research.

• AP1903 for Programmable FKBP Dimerization Assays

  2026-08-20

  AP1903 is an FKBP-binding ligand for precise chemical induction of protein proximity, apoptosis pathway research, and conditional cell ablation. This article explains how its quantitative benchmarks can guide assay design and how its logic complements multiplexed receptor-compatibility studies.

• Dabigatran etexilate: Direct Thrombin Inhibitor Workflows

  2026-08-19

  Dabigatran etexilate supports controlled coagulation-cascade modulation across plasma, platelet, conversion, and translational pharmacodynamic workflows. This guide shows how to distinguish prodrug conversion from direct thrombin inhibition, select sensitive readouts, and troubleshoot solvent, matrix, and timing effects.

• Chloroquine in Cementoblast Autophagy Research

  2026-08-18

  Chloroquine provides a rapid, titratable way to perturb lysosomal autophagy while studying compression-impaired cementoblast mineralization. This guide translates the periostin/β-catenin findings into practical dose screens, controls, endpoint choices, and troubleshooting strategies.

• Ribonuclease R for Circular RNA Workflows

  2026-08-18

  Ribonuclease R enables selective depletion of linear RNA, creating a practical route to circular RNA enrichment, validation, and RNA stability studies. This guide translates the circHIF1A/miR-486-5p/GRHL2 findings in lung adenocarcinoma into controlled RNase R workflows, assay choices, and troubleshooting strategies.

• Drug Response Assays: Proliferation Versus Cell Death

  2026-08-17

  Hannah Schwartz’s dissertation develops a more precise framework for interpreting anticancer drug responses by separating proliferative arrest from actual cell killing. Its findings show that drugs can influence both processes in different proportions and on different timelines, making paired, time-aware measurements essential for cancer research and preclinical assay design.

• Dual-Action Kinase Inhibitors and p38α Dephosphorylation

  2026-08-17

  The reference study shows that selected kinase inhibitors can do more than block p38α MAP kinase catalysis: they can also expose the activation-loop phosphothreonine to the WIP1 phosphatase. Biochemical assays and X-ray structures support a conformational mechanism that may guide the design of more potent and selective kinase inhibitors, although the findings remain primarily structural and in vitro.

• Poly (I:C): TLR3 Agonist for Innate Immunity

  2026-08-16

  Poly (I:C) is a synthetic double-stranded RNA analog used to activate TLR3-dependent innate immunity and interferon signaling. Its value is highest in controlled immunology, antiviral, inflammation, and dendritic-cell assays where delivery, cell type, and endpoint selection are explicitly defined.

454 records 7/31 page Previous Next First page 上5页 678910 下5页 Last page